Session Type
Meeting
Search Results for GLP-1
Oral Presentations
Abstract Number: 0007
SHM Converge 2025
Background: Glucagon-like peptide-1 (GLP-1) agonists are increasingly prescribed for obesity and type 2 diabetes, demonstrating efficacy in weight loss and glycemic control [1-3]. Beyond metabolic effects, these medications show protective effects against renal disease progression and reduce major adverse cardiovascular events [4]. GLP-1 agonists influence body composition through effects on both fat mass and fat-free [...]
Abstract Number: 153
SHM Converge 2024
Background: Semaglutide, a Glucagon-like peptide-1 (GLP-1) agonist, has become one of the most prescribed medications as a result of its beneficial cardiovascular profile and beneficial side effect of weight loss. There is a paucity in literature about its adverse effects. We aimed to conduct a meta-analysis of the severe adverse effects (SAE) of Semaglutide using [...]
Abstract Number: 568
SHM Converge 2021
Case Presentation: A 69-year-old male with T2DM, OSA, and chronic back pain presented to the ED with nausea, vomiting, malaise, and confusion. He had been on metformin for diabetes, and 6 days prior to presentation, was switched to Victoza (Liraglutide) for better glucose control. He lived at home with his wife, who noticed that his [...]
Oral Presentations
Abstract Number: 0007
SHM Converge 2025
Background: Glucagon-like peptide-1 (GLP-1) agonists are increasingly prescribed for obesity and type 2 diabetes, demonstrating efficacy in weight loss and glycemic control [1-3]. Beyond metabolic effects, these medications show protective effects against renal disease progression and reduce major adverse cardiovascular events [4]. GLP-1 agonists influence body composition through effects on both fat mass and fat-free [...]
Abstract Number: 0140
SHM Converge 2025
Background: Obstructive sleep apnea (OSA) is closely associated with obesity, and weight reduction is a critical component of its management. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonists have shown promise in promoting weight loss, potentially improving outcomes in OSA patients. We aimed to calculate the mean reduction in BMI and waist circumference after [...]
Abstract Number: 0583
SHM Converge 2025
Case Presentation: A 56-year-old female with past medical history of systemic lupus erythematosus (SLE) on hydroxychloroquine (HCQ) for 30 years, gastroesophageal reflux disease, autoimmune hepatitis on budesonide, asthma, and fibromyalgia presented to the emergency department (ED) with five days of worsening fatigue, bilateral lower extremity weakness, and pain. One week prior, she experienced nausea, heartburn, [...]
Abstract Number: 0646
SHM Converge 2025
Case Presentation: We report a case of a 35-year-old pregnant female with a history of type 2 diabetes complaint with only dulaglutide but not insulin, hypertension, and hyperlipidemia who presented with a two-day history of chills, shoulder pain, and reduced range of motion. She had a history of chronic left shoulder pain managed with intra-articular [...]
Abstract Number: 0804
SHM Converge 2025
Case Presentation: A 62-year-old female presented to the Emergency Department with 48 hours of persistent palpitations and a week of poor oral intake, polydipsia, and polyuria. Her past medical history included Type II Diabetes Mellitus treated long-term with metformin and dapagliflozin. Two weeks before presenting to the Emergency Department, she transitioned from dulaglutide to tirzepatide [...]
Abstract Number: 0818
SHM Converge 2025
Case Presentation: A 74-year-old male with a past medical history of type 2 diabetes presented with weakness, nausea, and weight loss. The patient was on metformin and glipizide at baseline, started on oral semaglutide and uptitrated to a dose of 14 mg one month prior to presentation. He reported a weight loss of 7 kg [...]